Evaluation of Pathological Manifestations of Disease in Mucopolysaccharidosis VII Mice after Neonatal Hepatic Gene Therapy
Molecular Therapy2002Vol. 6(6), pp. 745–758
Citations Over TimeTop 10% of 2002 papers
Lingfei Xu, Robert L. Mango, Mark S. Sands, Mark E. Haskins, N. Matthew Ellinwood, Katherine P. Ponder
Related Papers
- → Three Adult Siblings with Mucopolysaccharidosis Type II (Hunter Syndrome): A Report on Clinical Heterogeneity and 12 Months of Therapy with Idursulfase(2011)11 cited
- → Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases(2009)6 cited
- → Case Report: Mucopolysaccharidosis Type I Treatment With α-L-Iduronidase Replacement Therapy(2022)1 cited
- → Murine Mucopolysaccharidosis VII: Impact of Therapies on the Phenotype, Clinical Course, and Pathology in a Model of a Lysosomal Storage Disease(2001)38 cited
- → Intra-articular Enzyme Replacement Therapy with Recombinant Human Iduronidase is Safe and Well Tolerated in the Canine Model of Mucopolysaccharidosis Type I(2012)